The urgency behind the work is difficult to overstate. Since 2022, mpox outbreaks have emerged across multiple continents, and in 2024 a newly identified sublineage of clade I, designated Ib, triggered fresh waves of infection in several countries. The World Health Organization declared the ongoing outbreak a Public Health Emergency of International Concern on August 14, 2024, and its surveillance data recorded 52,845 confirmed cases and 215 deaths among confirmed cases globally between January and December 2025 alone. What makes clade I particularly alarming is its epidemiological profile. Transmission is no longer confined to sexual contact; confirmed household spread through close contact threatens pediatric populations, and in the current Democratic Republic of the Congo outbreak, children under 15 account for roughly 70 percent of confirmed cases and a staggering 88 percent of documented fatalities.

Clade I is also clinically distinct from clade II. Comparative studies have associated it with increased virulence, higher mortality, and more severe disease outcomes, demanding closer clinical oversight and earlier therapeutic escalation. This combination of enhanced transmissibility and heightened severity means that rapid clade discrimination is not merely a technical convenience. It is a fundamental requirement for real-time genomic surveillance, precise containment protocols, and rigorous epidemiological inquiry. PCR remains the WHO-endorsed reference assay for mpox detection, but its dependence on expensive thermal cycling equipment and its comparatively long turnaround time leave a critical gap at the point of care, particularly in resource-limited settings where clade I circulates most actively.

The new assay builds on the CRISPR/Cas12a system, an adaptive immune mechanism first identified in bacteria and archaea and now widely repurposed for viral pathogen detection. Cas12a possesses a distinctive property called trans-cleavage: once its guide RNA directs it to a matching DNA target, the enzyme promiscuously shreds nearby single-stranded DNA molecules. By flooding the reaction with single-stranded DNA reporters bearing a fluorescent tag and a quencher, researchers can convert the presence of a single target molecule into an explosive burst of fluorescence. Because Cas12a alone cannot amplify scarce templates, the system is typically paired with a pre-amplification step, and RPA has emerged as a favorite partner. Operating at just 37 to 42 degrees Celsius, RPA achieves exponential amplification within minutes using recombinase enzymes rather than heat-driven denaturation, making it an ideal match for field-deployable diagnostics.

The central engineering challenge in such combined systems is incompatibility. Premixing amplification reagents with CRISPR components in a single homogeneous reaction can actually degrade sensitivity, because premature activation of Cas12a during amplification may consume newly generated amplicons or the target templates themselves, throttling the amplification reaction before it reaches its full potential. The research team circumvented this problem with an elegantly simple physical solution: a compartmentalized tube sleeve consisting of an ordinary 1.5 milliliter microcentrifuge tube with the RPA mixture at its base, and an inverted, capless PCR tube nested inside it, held in place by surface tension and containing the preconfigured CRISPR/Cas12a detection mixture. During the 20-minute amplification at 39 degrees Celsius, the two reactions remain fully separated. A brief centrifugation then releases the CRISPR mixture into the amplified RPA reaction without ever opening the tube, minimizing both cross-contamination and aerosol exposure while allowing a further 20-minute incubation at 37 degrees Celsius to generate the fluorescent signal.

Optimization of the assay was methodical and thorough. The team produced its own LbCas12a protein in bacterial expression cells, achieving a purification purity of 96.98 percent as confirmed by thin-layer scanning, and validated its trans-cleavage activity with established positive and negative controls. Two candidate crRNAs, the guide RNAs that steer Cas12a to its target, were designed against clade I-specific conserved regions identified by comparative analysis of global MPXV genomes, and one, crRNA-I-2, produced markedly stronger fluorescence and was selected for further work. Titration experiments then pinned down the reaction cocktail: 187.5 nanomolar Cas12a protein, 25 nanomolar crRNA, and 1 micromolar single-stranded reporter, concentrations chosen to balance peak signal intensity against reagent cost. Among three RPA primer pairs, RPA-3-F/R showed the highest amplification efficiency, and a temperature gradient across 37, 39, and 42 degrees Celsius established 39 degrees as optimal.

The analytical performance figures are impressive for such a low-tech platform. Under optimized conditions, preliminary screening detected plasmid targets down to 43.7 copies per microliter, and a rigorous probit regression analysis across 20 replicates at each of five concentrations near the detection limit placed the 95 percent limit of detection at 27.16 copies per microliter, with a 95 percent confidence interval of 23.06 to 35.24 copies per microliter. All 20 replicates were positive at 43.70 copies per microliter, while detection fell to 15 of 20 at 21.85 copies and 6 of 20 at 10.93 copies, and vanished entirely below that. Specificity testing against a panel that included clade II plasmids, monkey B virus, cowpox virus, vaccinia virus, and varicella-zoster virus yielded robust fluorescence exclusively for clade I, with no cross-reactivity whatsoever. Repeatability was similarly strong, with intra-assay coefficients of variation ranging from 1.032 to 8.509 percent and inter-assay coefficients spanning 2.279 to 8.483 percent across three independent runs on different days, and negative controls remained negative throughout.

Notably, the assay retained meaningful sensitivity even without any incubator at all. At room temperature, 25 degrees Celsius, the platform reliably detected targets at 437 copies per microliter, though signal strength attenuated at lower concentrations. While this ambient-temperature performance does not match the optimized thermostated conditions, the researchers emphasize that it confirms the assay remains viable in field settings where heating devices are simply not an option. The visual readout itself is deliberately accessible: results are documented with a handheld blue-light transilluminator or even a smartphone camera, and green-channel pixel intensities extracted with image analysis software provide an objective, quantifiable measure that removes subjectivity from result interpretation.

Head-to-head evaluation against qPCR in simulated clinical samples provided perhaps the most compelling evidence of the assay’s practical value. The team spiked recombinant plasmid into total DNA extracted from Vero cells and human embryonic kidney 293T cells, generating a panel of 32 simulated samples including negative controls. Using a pixel-value threshold of 40 to distinguish signal from background, the RPA-CRISPR/Cas12a assay detected 10 of 14 spiked samples in both the Vero cell and 293T cell DNA backgrounds. Standard qPCR, run in parallel with a Ct cutoff of 35 and a requirement for a typical sigmoidal amplification curve, managed only 7 of 14 in the Vero background and 8 of 14 in the 293T background. The researchers attribute the undetected samples in both methods to target concentrations genuinely below each assay’s analytical detection limit rather than random false negatives or instability, but the outcome demonstrates that the low-equipment platform actually outperformed the laboratory-bound reference method on low-copy samples within the simulated matrices.

The authors are candid about the limitations that remain before this assay can reach clinics and field stations. crRNA design is constrained by restrictive protospacer adjacent motif requirements and by the remarkably high sequence homology, 96.8 percent, between clades I and II, though alternative Cas systems such as Cas13 and Cas14 could relax these constraints in future iterations. More significantly, the analytical evaluation relied primarily on recombinant plasmids, and while simulated samples with cellular DNA backgrounds offered a preliminary reality check, they cannot fully reproduce viral particle lysis, extraction efficiency, or the complexities of genuine clinical matrices. Validation with authentic clinical specimens or pseudovirus-based samples was not possible owing to biosafety requirements and the unavailability of clade I clinical material, and the researchers acknowledge that such evaluation will be essential. Even so, the assay fills a specific niche within an integrated diagnostic strategy: a universal mpox test would first confirm infection, after which this clade I-specific assay could stratify risk, guide clinical escalation, and sharpen surveillance of the lineage now driving the world’s most dangerous mpox outbreaks. With a 40-minute workflow, a visual readout, and no need for sophisticated equipment, it represents a practical step toward decentralized detection precisely where it is needed most.

Subject of Research: Development of a rapid one-pot RPA-CRISPR/Cas12a assay with visual readout for clade I-specific detection of monkeypox virus

Article Title: One‐Pot RPA‐CRISPR/Cas12a Assay With Visual Readout for the Ultra‐Specific Detection of Monkeypox Virus Clade I

Article References: Li, B., Liu, L., Jin, K., Huang, Z., Zhang, T., Gao, R., Chen, H., Niu, L., Fan, C., Zhang, H., Huang, P., & Wang, H. (2026). One‐Pot RPA ‐ CRISPR /Cas12a Assay With Visual Readout for the Ultra‐Specific Detection of Monkeypox Virus Clade I. Microbial Biotechnology, 19(9), Article e70437. https://doi.org/10.1111/1751-7915.70437

Image Credits: AI Generated

DOI: 10.1111/1751-7915.70437

Keywords: mpox, monkeypox virus, CRISPR/Cas12a, recombinase polymerase amplification, clade I, point-of-care diagnostics, isothermal amplification, crRNA, outbreak surveillance, limit of detection, visual readout, qPCR

The urgency behind the new assays is difficult to overstate. Since its first detection in January 2022, highly pathogenic avian influenza H5 has infected more than 13,000 wild birds and roughly 173 million poultry, with economic losses estimated between 14 and 164 billion dollars. In March 2024, an unprecedented spillover of clade 2.3.4.4b A(H5N1) into dairy cattle was reported in Texas, and the virus has since spread across 17 US states, infecting more than 1,000 cattle herds with sustained mammalian transmission and 70 human cases reported as of June 3, 2025. Historically, HPAI outbreaks such as H5N1 in Hong Kong in 1997 and H7N9 in China in 2013 have produced case fatality rates of at least 30 percent in humans, underscoring the pandemic potential that hangs over every new host adaptation.

Current diagnostic approaches each carry trade-offs that limit their usefulness in the field. Virus isolation remains the gold standard but is confined to biosafety level-3 laboratories staffed by highly trained personnel. Rapid immunoassays deliver results in about 15 minutes but suffer from reduced sensitivity and cannot discriminate between viral clades. Reverse transcription PCR offers high sensitivity and adaptability yet depends on thermocycling equipment and skilled operators, while next-generation sequencing provides nucleotide-level resolution at the cost of high expense and long turnaround times. The result, the authors argue, is a diagnostic landscape in which the tools that respond fastest to outbreaks are either too insensitive or too infrastructure-dependent to support surveillance at farms, markets, and rural clinics where spillovers first emerge.

To close this gap, the team turned to SHINE, short for Streamlined Highlighting of Infections to Navigate Epidemics, a one-pot CRISPR diagnostic platform previously developed for SARS-CoV-2 and influenza detection. In the avian influenza version of the workflow, viral RNA undergoes reverse transcription, recombinase polymerase amplification, and T7 transcription within a single tube, generating RNA amplicons that activate the collateral cleavage activity of the Cas13a enzyme when they base-pair with a complementary CRISPR RNA guide. Activated Cas13a then cuts RNA reporters, producing either a fluorescent signal read out on a plate reader or a colorimetric band on a paper lateral flow strip, the latter requiring nothing more sophisticated than a smartphone camera to document.

Assay design leaned heavily on machine learning. The researchers used ADAPT, a software platform that predicts sensitive and specific Cas13 guide sequences, to select primer and crRNA sets targeting the hemagglutinin gene segment that uniquely defines H5 viruses. Two candidate designs achieved predicted coverage of 98.72 and 96.18 percent of aligned H5N1 sequences, and the top-performing guide, targeting nucleotides 847 to 874 of the H5 consensus, was carried forward. A series of optimization experiments followed: the team tuned the ratio of T7-attached to non-T7-attached forward primers, settled on a 1:3 ratio that reduces competition between amplification and detection, increased RPA primer concentrations, and adjusted reporter, RNase H, and magnesium levels. The resulting optimized assay, SHINE-H5, reliably detected synthetic RNA targets across all tested concentrations within 60 minutes, a substantial improvement over the prototype.

Analytical characterization of SHINE-H5 was rigorous. Testing against six vaccine-derived viral seedstocks from the CDC showed high fluorescence for the intended target and negligible signal for non-target viruses. Clinical specificity was evaluated using 64 nasopharyngeal swab specimens from Massachusetts General Hospital that tested positive for seasonal influenza A or B but negative for avian H5 by qPCR; SHINE-H5 correctly returned negative results for all 64 samples, covering infections with H1N1, H3N2, and influenza B, including co-infections. The limit of detection, established with serial dilutions of H5N1 viral seedstock in viral transport media and a logistic regression model requiring at least 95 percent detection, was 121.7 copies per microliter, with a 95 percent confidence interval of 63.14 to 234.55 copies per microliter. In a head-to-head comparison, a validated RT-qPCR assay detected samples down to 10 copies per microliter while SHINE-H5 detected down to 50 copies per microliter, a sensitivity gap the authors acknowledge but one that still significantly outperforms existing H5 immunoassays.

For field deployment, the researchers adapted SHINE-H5 to a lateral flow readout, replacing the fluorescent quenched reporter with a FAM-biotin reporter whose cleavage products migrate on a paper strip. Using a larger 40-microliter reaction volume, the lateral flow version detected H5N1 seedstock down to 25 copies per microliter while retaining strong specificity against a subset of 14 seasonal influenza-positive patient samples. The team also demonstrated that the assay can detect synthetic RNA targets spiked into milk, a proof of concept for surveillance in the dairy herds now at the center of the North American outbreak.

Beyond broad H5 detection, the study introduces SHINE-H5-CS, a clade-specific assay targeting 2.3.4.4b A(H5N1), the lineage that has dominated global H5 phylogeny since 2021 and is driving the US cattle outbreak. Guide design for this assay employed BADGERS, a successor to ADAPT that integrates advanced search algorithms to explore the fitness landscape of candidate crRNAs and achieve single-nucleotide discrimination. Of three candidates, crRNA3, targeting a region of the H5 segment starting at nucleotide position 880, showed the highest on-target activity with minimal off-target signal. The researchers also shifted the forward primer four nucleotides upstream to introduce an additional mismatch that sharpened discrimination. SHINE-H5-CS consistently detected clade 2.3.4.4b RNA at concentrations above 100 copies per microliter while showing minimal cross-reactivity with non-2.3.4.4b H5 sequences and seasonal influenza seedstocks, enabling lineage identification without sequencing.

The team extended the platform to the H7 subtype, the other hemagglutinin group with well-documented potential to evolve into highly pathogenic strains. Phylogenetic analysis of 25 representative H7 strains revealed clean separation into Eurasian and North American lineages that mirror migratory bird flyways, and the 2013 Eurasian H7N9 epidemic, which caused more than 1,500 human infections with a fatality rate near 40 percent, demonstrated the public health stakes of this lineage. The resulting SHINE-H7-Eurasian assay reliably detected Eurasian H7 RNA across a range of concentrations while discriminating against North American H7 strains and a panel of unrelated seasonal influenza viruses, and it too was adapted to a lateral flow format that preserved lineage specificity.

The authors are candid about the limitations of the work. Confirmed human H5 and Eurasian H7 cases remain rare, so the assays could not be evaluated on true positive human clinical specimens, and compatibility with specimen types beyond mock milk samples, such as poultry or environmental samples, has not yet been assessed. Even so, the combination of isothermal operation at 37 degrees Celsius, turnaround times of 60 to 120 minutes, minimal instrumentation, machine-learning-accelerated assay design, and compatibility with paper-based readouts positions the SHINE family of assays as a practical bridge between laboratory-grade accuracy and point-of-need accessibility. As avian influenza continues its advance through wild birds, poultry, cattle, and occasionally people, tools that can detect not just the virus but its specific clades, close to where it emerges, may prove decisive in blunting the next spillover before it becomes the next pandemic.

Subject of Research: Development of streamlined one-pot CRISPR-Cas13 diagnostic assays for detection and genetic subtyping of H5 and H7 avian influenza viruses

Article Title: Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza

Article References: Huang, Y., Guo, A., Adams, G., Lemieux, J. E., & Myhrvold, C. (2026). Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza. iScience, 29(10), Article 117556. https://doi.org/10.1016/j.isci.2026.117556

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117556

Keywords: avian influenza, CRISPR diagnostics, SHINE assay, Cas13, H5N1, H7 avian influenza, clade 2.3.4.4b, lateral flow assay, recombinase polymerase amplification, point-of-need testing, dairy cattle outbreak, pandemic preparedness

The platform, named HOMEBRED for highly sensitive and specific omnipresent multiplex endonuclease-based reliable detection, is built on the SHERLOCK architecture that harnesses the CRISPR-associated protein Cas13a. When Cas13a finds the RNA sequence its guide molecule instructs it to find, it does not merely cut the target; it shreds any nearby RNA indiscriminately. This collateral cleavage activity is the engine of the assay. Synthetic RNA reporters carrying a fluorescent dye and a quencher float in the reaction; if the target is present, the reporters are cleaved, the fluorescence escapes, and the result can be read with the naked eye under an inexpensive handheld blue light or on paper-based lateral flow strips. No thermocycler, no sequencer, no fluorescence plate reader is required at any stage.

What separates HOMEBRED from earlier CRISPR diagnostics is the way its guide RNAs are chosen. Fragile crRNA target windows have been a chronic vulnerability in CRISPR-based tests, because a single mutation in the target sequence can silence the assay entirely, allowing an evolving pathogen to escape detection. The team addressed this with CaSilico, an automated computational pipeline that screens thousands of genome sequences to identify highly conserved, mutation-resistant regions. For foot-and-mouth disease virus, one of the most genetically variable livestock pathogens known, CaSilico analyzed 707 sequences of the conserved 3D gene across all seven serotypes, applying a 98 percent conservation threshold and yielding 41 candidate target sites from which two crRNAs were selected using stringent thermodynamic and specificity criteria.

That computational rigor proved consequential in practice. One of the two initial foot-and-mouth disease virus crRNAs, CR3D1, looked ideal on paper yet failed to detect the virus in the laboratory. When the researchers examined its predicted secondary structures in detail, they found that the centroid structure, not just the minimum free energy fold, deviated from the stable hairpin architecture that Cas13a requires for recognition. This failure mode has been observed by other groups, and the finding underscores a lesson increasingly clear in the field: guide RNA design must weigh thermodynamic structure predictions as carefully as sequence conservation. The redesigned guide, CR3D2, worked flawlessly, correctly classifying all 11 clinical samples in complete agreement with reference RT-qPCR, with detection limits reaching down to ten copies per microliter in both fluorescent and lateral flow formats.

Perhaps the most consequential demonstration involves brucellosis, a bacterial zoonosis that infects an estimated 300 million of the world’s 1.4 billion cattle and for which no human vaccine exists. Veterinary control programs face a stubborn problem known as DIVA, the inability to differentiate infected animals from vaccinated ones. A false positive in a vaccinated, high-breeding-value animal can trigger needless culling, while a missed infection lets the disease spread silently. HOMEBRED tackles this with a dual-crRNA architecture: one guide targets the conserved bcsp31 gene to detect the four major Brucella species, while a second exploits a deletion mutation in the narJ gene unique to the RB51 vaccine strain. In testing, the platform signaled every wild-type culture of B. melitensis, B. abortus and B. suis while remaining silent against the vaccine strain, achieving 100 percent concordance with reference PCR across all 14 samples tested.

The platform also ventures into oncology. BCR-ABL1 fusion transcripts, produced when chromosomes 9 and 22 break and rejoin, are the hallmark of chronic myeloid leukemia, and the specific transcript isoform a patient carries influences response to tyrosine kinase inhibitor therapy. HOMEBRED distinguished the e13a2, e14a2 and e1a2 isoforms using isoform-specific guide RNAs and recombinase polymerase amplification primers sharing a common reverse primer on the ABL1 gene. Validated against the KCL-22 and K-562 leukemia cell lines and 14 clinical samples, the assay matched Sanger sequencing in specificity and exceeded RT-qPCR in sensitivity. Strikingly, three samples that reference RT-qPCR had called negative were positive by HOMEBRED, and two patients were found to co-express two transcript types simultaneously, findings with direct implications for treatment selection and minimal residual disease monitoring.

Two reaction formats were compared head to head. The two-step assay runs amplification and detection in separate tubes, while the single-step format folds both into one pot, reducing handling time and contamination risk. For Brucella, the one-pot version matched the two-step version perfectly, but for foot-and-mouth disease virus it dropped to 77 percent agreement, missing three positives and losing roughly an order of magnitude in detection limit. The authors conclude that the two-step format remains the safer default when sensitivity is paramount, reserving the single-step format for targets where its performance is proven. All duplicate reactions across both formats achieved 100 percent qualitative concordance, 111 out of 111 pairs, a reproducibility figure that speaks to careful optimization.

The extraction-free capability is where HOMEBRED pushes furthest past the existing literature. Traditional purification, when skipped, usually devastates sensitivity because crude biological matrices carry enzymatic inhibitors such as hemin and polysaccharides. The team paired their assay with HUDSON, a method that heats samples with chemical reducers to destroy nucleases and release genetic material, and applied it directly to vesicular fluid and epithelial tissue from foot-and-mouth disease cases. Without any nucleic acid extraction, the workflow detected viral seedstock down to 3.23 times ten to the fourth plaque-forming units per milliliter by colorimetric readout and 3.23 times ten to the third by fluorescence, an improvement of up to two orders of magnitude over comparable extraction-free CRISPR assays. The strategic choice of epithelial tissue, which proves far more chemically compatible with the HUDSON reaction than blood or feces, appears central to this performance.

Robustness against real-world genetic drift was verified by sequencing. Sanger analysis of foot-and-mouth disease virus samples confirmed that the computationally designed target region stayed fully conserved across strains, with a single substitution in one sample that failed to impair detection. Two leukemia clinical samples harbored point mutations inside the protospacer region, and HOMEBRED still called both correctly with no signal loss. The choice of Cas13a over the Cas12a enzymes used in several rival platforms also matters here: Cas13a requires no protospacer adjacent motif, freeing guide design from target-site constraints that are particularly restrictive when isolating the narrow junctions of fusion transcripts, and its vigorous trans-cleavage activity sustains signal generation even at suboptimal temperatures.

The authors acknowledge limits. Clinical isolates of B. canis could not be physically tested due to regional availability, so the team verified the assay against synthetic DNA carrying the identical conserved bcsp31 target domain, supported by sequence alignments showing 100 percent identity. No accessible cell line expressing the minor e1a2 transcript was available for extended in vitro benchmarking. Future work, they write, should prioritize lyophilized reagent formulations to round out farm-level deployment. Even with those caveats, HOMEBRED demonstrates that a single CRISPR platform, guided by automated conserved-region design and read by nothing more sophisticated than a handheld blue light, can deliver sensitivity on par with PCR across livestock pathogens, zoonotic bacteria, respiratory viruses and leukemia biomarkers, a convergence that could materially narrow the diagnostic gap between well-resourced laboratories and the places where early detection matters most.

Subject of Research: A CRISPR-Cas13a diagnostic platform enabling instrument-free detection of infectious agents and oncogenic mutations

Article Title: HOMEBRED: A unified CRISPR platform for field-ready shadowing of infectious agents and oncogenic mutations

Article References: Asadbeigi, A., Fazilaty, H., Saffari, M., Shirkoohi, R., Modarressi, M. H., Salehi, A., & Bakhtiarizadeh, M. R. (2026). HOMEBRED: A unified CRISPR platform for field-ready shadowing of infectious agents and oncogenic mutations. iScience, 29(10), Article 117532. https://doi.org/10.1016/j.isci.2026.117532

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117532

Keywords: CRISPR diagnostics, Cas13a, SHERLOCK, HOMEBRED, foot-and-mouth disease virus, brucellosis, SARS-CoV-2, BCR-ABL1, chronic myeloid leukemia, recombinase polymerase amplification, DIVA, point-of-care testing